Compositions comprising magnetic iron oxide particles and use thereof in medical imaging

A magnetic iron oxide, iron oxide technology, applied in applications, drug delivery, nano-drugs, etc., can solve problems such as difficulty in widespread application and expensive MRI diagnosis

Inactive Publication Date: 2009-03-04
BAYER SCHERING PHARMA AG +1
View PDF18 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This is because, unlike in MRI, in MPI there is no need for a large homogeneous magnetic field and thus a

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions comprising magnetic iron oxide particles and use thereof in medical imaging
  • Compositions comprising magnetic iron oxide particles and use thereof in medical imaging
  • Compositions comprising magnetic iron oxide particles and use thereof in medical imaging

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] Example 1: Preparation of Magnetic Iron Oxide Particles

Embodiment 1a

[0082] Example 1a) Preparation of Starting Particle Dispersion

[0083] 105 g of carboxydextran (CDX) with an intrinsic viscosity of 0.050 dl / g was dissolved in 350 ml of water. Thereto were added 13.6 g of an aqueous solution of iron(II) chloride tetrahydrate and 140 ml of 1M iron(III) chloride solution (corresponding to 37.8 g of iron(III) chloride hexahydrate) under a supply of nitrogen gas. Then, 242 ml of 3N NaOH solution was added thereto over 15 minutes, stirred while adding, and the mixture was heated to 80°C. The pH was adjusted to 7.0 by adding 6N HCl. The mixture was stirred at reflux for another 1 hour.

[0084] After cooling, the samples were centrifuged (2100 g / 30 minutes). Ethanol was added in a proportion corresponding to 78% of the volume of the pellet supernatant. The samples were centrifuged again (2100 g / 10 min). The precipitate was dissolved in water and dialyzed against water (16h). The dialyzate was adjusted to pH 7.2 with NaOH and concentrated und...

Embodiment 1b

[0086] Embodiment 1b) Preparation of small particles

[0087] The magnetic filter consisted of a ring magnet (NE 1556 IBS Magnet Berlin, 15mm outer diameter, 5mm inner diameter, 6mm height) and a separation chamber installed in the inner volume of the ring magnet. The separation chamber consists of walls made of plastic and is filled with iron beads (approximately 0.3 mm in diameter). Mix 0.8ml with an iron content of 500mmol / l and T 2 The relaxivity is about 240 (mM·s) -1 A dispersion of iron oxide particles (according to Example 1a) was filtered through a magnetic filter by means of hydrostatic pressure. T of the filtrate thus obtained 2 The relaxivity is 41 (mM·s) -1 .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Overall diameteraaaaaaaaaa
Diameteraaaaaaaaaa
Login to view more

Abstract

The present invention relates to complexes which contain magnetic iron oxide particles in a pharmaceutically acceptable shell, said particles having a diameter of 20 nm to 1 [mu]m with an overall particle diameter/core diameter ratio of less than 6, and to the use of these complexes in magnetic particle imaging (MPI). Particular preference is given to the use of these compositions in examining the gastrointestinal tract, the vascular system of the heart and cranial components, in the diagnosis of arteriosclerosis, infarctions, and tumors and metastases, for example of the lymphatic system.

Description

technical field [0001] The present invention relates to complexes containing magnetic iron oxide particles (magnetic iron oxide particles) in a pharmaceutically acceptable shell, said particles having a diameter of 20 nm to 1 μm, the ratio of total particle diameter / core diameter is less than 6, and these Use of the complex in Magnetic Particle Imaging (MPI). Particular preference is given to the use of these compositions in the examination of the gastrointestinal tract, the vasculature of the heart and cranial parts, in the diagnosis of arteriosclerosis, infarction, and tumors and metastases, eg of the lymphatic system. Background technique [0002] In imaging methods, especially in the medical diagnostics sector, contrast agents have led to considerable contrast improvements in conventional imaging methods such as X-ray diagnostics and magnetic resonance imaging (MRI). Contrast agents useful in MRI can be differentiated according to their mechanism of action (positive amp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K49/18
CPCA61K49/1875A61B5/411A61B5/0515A61B5/416B82Y5/00A61K49/1866A61B5/418A61K49/1836A61K49/1863A61B5/415
Inventor A·布里尔B·格莱克J·韦泽内克M·罗勒H·-J·韦因曼H·皮特什R·拉瓦泽克M·罗塞J·汤森
Owner BAYER SCHERING PHARMA AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap